Passage Bio shares are trading lower after the company announced the FDA did not support a single-arm trial design for its indication in the Type C meeting and instead indicated that a randomized controlled trial would be required for registrational purposes. Also, the company announced it initiated a review of strategic alternatives to maximize shareholder value.

PASG

IBBQ

LABU

SBIO

<p>Passage Bio shares are trading lower after the company announced the FDA did not support a single-arm trial design for its indication in the Type C meeting and instead indicated that a randomized controlled trial would be required for registrational purposes. Also, the company announced it initiated a review of strategic alternatives to maximize shareholder value.</p>

benzinga_article

Passage Bio

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

News